1. Jebeile H, Kelly AS, O’Malley, et al. Obesity in children and adolescents: epidemiology, causes, assessment, and management. Lancet Diabetes Endocrinol 2022; 10: 351-365.
2.
Weihrauch-Blüher S, Schwarz P, Klusmann JH. Childhood obesity: increased risk for cardiometabolic disease and cancer in adulthood. Metabolism 2019; 92: 147-152.
3.
Kucharska M, Daniluk U, Kwiatek-Średzińska KA, et al. Hepatobiliary manifestations of inflammatory bowel disease in children. Clin Exp Hepatol 2019; 5: 203-209.
4.
Kotsiliti E. Liver steatosis and fibrosis in China. Nat Rev Gastroenterol Hepatol 2023; 20: 631.
5.
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78: 1966-1986.
6.
Bobrus-Chociej A, Flisiak-Jackiewicz M, Daniluk U, et al. Estimation of gamma-glutamyl transferase as a suitable simple biomarker of the cardiovascular risk in children with non-alcoholic fatty liver disease. Acta Biochim Pol 2018; 65: 539-544.
7.
Zdanowicz K, Flisiak-Jackiewicz M, Bobrus-Chociej A, et al. Thrombospondin-2 as a potential noninvasive biomarker of hepatocyte injury but not liver fibrosis in children with MAFLD: A preliminary study. Clin Exp Hepatol 2023; 9: 368-374.
8.
Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatology (Oxford) 2019; 58: 2177-2180.
9.
Copur S, Demiray A, Kanbay M. Uric acid in metabolic syndrome: Does uric acid have a definitive role? Eur J Intern Med 2022; 103: 4-12.
10.
Peng L, Wu S, Zhou N, et al. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity. BMC Pediatr 2021; 21: 122.
11.
Mohamed RZ, Jalaludin MY, Anuar Zaini A. Predictors of non-alcoholic fatty liver disease (NAFLD) among children with obesity. J Pediatr Endocrinol Metab 2020; 33: 247-253.
12.
He L, Qiu K, Zheng W, et al. Uric acid may serve as the sixth cardiometabolic criterion for defining MASLD. J Hepatol 2024; 80: e152-e153.
13.
de Onis M, Onyango AW, Borghi E, et al. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 2007; 85: 660-667.
14.
Kułaga Z, Świąder-Leśniak A, Kotowska A, et al. Population-based references for waist and hip circumferences, waist-to-hip and waist-to-height ratios for children and adolescents, and evaluation of their predictive ability. Eur J Pediatr 2023; 182: 3217-3229.
15.
Zimmet P, Alberti KG, Kaufman F, et al. The metabolic syndrome in children and adolescents – an IDF consensus report. Pediatr Diabetes 2007; 8: 299-306.
16.
Muriel P, López-Sánchez P, Ramos-Tovar E. Fructose and the liver. Int J Mol Sci 2021; 22: 6969.
17.
Lee SJ, Oh BK, Sung KC. Uric acid and cardiometabolic diseases. Clin Hypertens 2020; 26: 13.
18.
Yanai H, Adachi H, Hakoshima M, et al. Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments. Int J Mol Sci 2023; 24: 15473.
19.
Di Sessa A, Guarino S, Umano GR, et al. Uric acid in pediatric MASLD definition: Is it time to implement diagnostic criteria?
20.
J Hepatol 2024; 80: e254-e255.
21.
Mosca A, Nobili V, De Vito R, et al. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. J Hepatol 2017; 66: 1031-1036.
22.
Kim A, Yang HR, Cho JM, et al. A nomogram for predicting non-alcoholic fatty liver disease in obese children. Pediatr Gastroenterol Hepatol Nutr 2020; 23: 276-285.
23.
Cardoso AS, Gonzaga NC, Medeiros CC, et al. Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents. J Pediatr (Rio J) 2013; 89: 412-418.
24.
Liu Z, Wang Q, Huang H, et al. Association between serum uric acid levels and long-term mortality of metabolic dysfunction-associated fatty liver disease: a nationwide cohort study. Diabetol Metab Syndr 2023; 15: 27.
25.
Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD. J Hepatol 2024; 80: e62-e64.
26.
Al-Shargi A, El Kholy AA, Adel A, et al. Allopurinol versus Febuxostat: A new approach for the management of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease. Biomedicines 2023; 11: 3074.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
